FDA approves landmark pancreatic cancer drug that’s shown to improve survival
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"FDA approves landmark pancreatic cancer drug that’s shown to improve survival" is generating significant coverage in the Business category, with 3 articles from 3 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Pancreatic Cancer Action Network, WGME and AP News. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 83d ago.
Quick answers
Why is "FDA approves landmark pancreatic cancer drug that’s shown to improve survival" trending?
Because 3 independent news sources published 3 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (9)
- New FDA-approved drug offers hope in pancreatic cancer treatment : Here & Now Anytime NPR · 83d ago
- As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground Fierce Pharma · 83d ago
- FDA approves breakthrough drug daraxonrasib to treat pancreatic cancer BBC · 83d ago
- FDA approves landmark pancreatic cancer drug that's shown to improve survival Dallas News · 83d ago
- University of Cincinnati Cancer Center helps develop landmark pancreatic cancer drug WLWT · 83d ago
- FDA approves new pancreatic cancer drug that could extend patients' lives CBS News · 83d ago
- FDA Approves RASONQUE™ (daraxonrasib) Pancreatic Cancer Action Network · 83d ago
- Stage 4 Maine cancer patient says new FDA-approved pill is buying him time WGME · 83d ago
- FDA approves landmark pancreatic cancer drug that’s shown to improve survival AP News · 83d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.